title: Efficacy and tolerance of HCV treatment in HIV-HCV coinfected patients: the potential interaction of PI treatment.
abstract: OBJECTIVE
  To evaluate tolerance and efficacy of an open-label interferon-ribavirin treatment and their determinants in 62 HCV-HIV coinfected patients in routine followup.
  
  
  METHODS
  Patients received at least 6 and up to 12 months of combination interferon alpha-2b (peg or not) plus ribavirin. Determinants of therapeutic success were estimated by a multivariate logistic regression.
  
  
  RESULTS
  Five patients stopped the study, 4 were lost to follow-up, and 53 participated in the entire therapeutic protocol. Among these 53, the end-of-treatment results showed complete clearance of HCV-RNA in 17 (32%). A sustained virologic response (SVR) after 6 or 9 months was observed in 9 (17%) patients, 3 relapsed, and data were not available for 5. Genotype 3a (odds ratio [OR] = 14.4; confidence interval [CI] = 1.84-110.3) favored SVR and treatment with protease inhibitor (PI) therapeutic resistance (OR = 14.4; CI = 1.01-200); as well, a higher fibrosis score tended to increase resistance (p =.11). Adverse events were reported by 24/53 patients (45.3%).
  
  
  CONCLUSIONS
  HCV therapy associating interferon and ribavirin in HCV-HIV coinfected patients is well accepted even if tolerance is moderate. Treatment permitted SVR in at least 17% of the cases. This is likely when patients initiate treatment at the early fibrosis stage and are infected with genotype 3a. The potential interaction with PI therapy should be explored.
authors.affiliation: CISIH-Sud, Département de Recherche Clinique (RCCS), Hôpital Sainte-Marguerite, CHU de Marseille, France.
authors.forename: I
authors.initials: I
authors.lastname: Poizot-Martin
authors.forename: C
authors.initials: C
authors.lastname: Marimoutou
authors.forename: S
authors.initials: S
authors.lastname: Benhaim
authors.forename: M-P
authors.initials: MP
authors.lastname: Drogoul-Vey
authors.forename: T
authors.initials: T
authors.lastname: Dinh
authors.forename: F
authors.initials: F
authors.lastname: Vion-Dury
authors.forename: V
authors.initials: V
authors.lastname: Frixon-Marin
authors.forename: C
authors.initials: C
authors.lastname: Tamalet
authors.forename: J-A
authors.initials: JA
authors.lastname: Gastaut
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D004347:Drug Interactions; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D017320:HIV Protease Inhibitors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a